AMG623 peptibody: Clinical Trials

4 completed, 4 withdrawn, 1 terminated. 6 Phase 3, 5 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	6	Withdrawn 3, Completed 2, Terminated 1
Phase 2	5	Completed 3, Withdrawn 2

Follow AMG623 peptibody: new trials by email Literature Review of AMG623 peptibody trials Research Report on AMG623 peptibody

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Blisibimod, Placebo - Systemic Lupus Erythematosus	Phase 3	Terminated	Anthera Pharmaceuticals	3	2016-06-01	2017-05-23
MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP Blisibimod, Placebo - Immune Thrombocytopenic Purpura, Idiopathic Thrombocytopenic Purpura	Phase 2 / Phase 3	Withdrawn	Anthera Pharmaceuticals		2015-12-01	2015-07-30
CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Blisibimod, Placebo - Systemic Lupus Erythematosus	Phase 3	Withdrawn	Anthera Pharmaceuticals		2015-12-01	2015-08-13
BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis Blisibimod, Placebo - Granulomatosis With Polyangiitis, Microscopic Polyangiitis	Phase 2	Withdrawn	Anthera Pharmaceuticals		2014-12-01	2015-07-30
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy Blisibimod, Placebo - IgA Nephropathy	Phase 3	Withdrawn	Anthera Pharmaceuticals		2014-10-01	2015-07-30
BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration Blisibimod, Placebo - IgA Nephropathy	Phase 2 / Phase 3	Completed	Anthera Pharmaceuticals	57	2013-06-01	2017-09-18
CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus blisibimod, Placebo - Systemic Lupus Erythematosus	Phase 3	Completed	Anthera Pharmaceuticals	442	2013-02-01	2017-02-03
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 A-623 - Systemic Lupus Erythematosus	Phase 2	Completed	Anthera Pharmaceuticals	382	2011-04-01	2014-02-13
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus A-623, Placebo Comparator - Systemic Lupus Erythematosus	Phase 2	Completed	Anthera Pharmaceuticals	547	2010-07-01	2014-03-04

Conditions studied

Autoimmune Diseases (5)  ·  Lupus Erythematosus, Systemic (5)  ·  Glomerulonephritis, IGA (2)  ·  Nephritis (2)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1)  ·  Granulomatosis with Polyangiitis (1)  ·  Kidney Diseases (1)  ·  Microscopic Polyangiitis (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)

Sponsors

Anthera Pharmaceuticals (9)

Countries

Hong Kong (4)  ·  Philippines (4)  ·  Taiwan (4)  ·  Brazil (3)  ·  Colombia (3)  ·  India (3)  ·  Mexico (3)  ·  Argentina (2)  ·  Chile (2)  ·  Georgia (2)  ·  Malaysia (2)  ·  Peru (2)  ·  Singapore (2)  ·  South Korea (2)  ·  Thailand (2)

Results publications

PMID 33687069, PMID 24748629, PMID 26032537, PMID 29563108